Small Molecule Injectable Drugs Offer Several Advantages Due To Which They Are Widely Being Adopted In Medical Industry
One of the key advantages of Small Molecule Injectable Drugs is their easy synthesizability and low cost. Small molecule drugs are also easy to manufacture, which leads to fierce generic competition that lowers their profit margins after their patents expire. Small molecule drugs can target various biochemical substrates, including intracellular proteins and nucleic acids.
However, some biological targets may not be druggable, which is one of the main reasons why these drugs are not widely available. Moreover, many bacterial and cancer cells have developed resistance to small molecule drugs, through a variety of mechanisms, including chemoenzymatic modifications, efflux pumps, and mutations in the target protein.
The major Advantage of Small Molecule Injectable Drugs Market is that they are easy to deliver into cells, which makes them more efficient therapeutics. They can also penetrate cell membranes and reach intracellular targets. Small molecule drugs are used in the treatment of diseases that are caused by genetic defects, infectious diseases, blood diseases, and cardiovascular issues. Small molecule drugs are also safer than large molecule drugs. This low molecular weight also makes it possible to administer these drugs to patients.
Among the most important features of an injectable drug is its high level of sterility and reliability. While speed and cost are important, reliability should not be sacrificed for speed. Grifols' automation technology has greatly reduced the risk of contamination and error, thus ensuring the safety of patients and operators. The company is committed to meeting the requirements of these standards to develop quality injectable drugs for patients.
Small molecule drugs are derived from simple chemical compounds and can be manufactured through chemical synthesis. Their molecular mass ranges between twenty to 100 atoms. They are easier to synthesize and administer than biologics. Unlike biologics, Small Molecule Injectable Drugs can pass through cell membranes. They also have a broad range of routes of administration.
Among these routes are intravenous and subcutaneous injections. In March 2021, the Therapeutic Discovery division and Orionis biosciences of the University of Texas MD Anderson Cancer Center launched Project Helios to unlock novel approaches in small molecule drug discovery.
Comments
Post a Comment